Tariq and Rasool published that, in cases of culture-proven sepsis, among Enterobacteriaceae, 31.82% were
K. species (
K. pneumonia and
K. oxytoca) (
14). This becomes more relevant because
K. pneumoniae,
K. variicola, and
K. quasipneumoniae are difficult to differentiate phenotypically, leading to misinterpretation of their infection prevalence (
6,
15,
16). In fact, to our knowledge, there is no biochemical test capable of differentiating these 3
Klebsiella species concomitantly during routines in clinical microbiology laboratories. A very important issue to take into account is that
Klebsiella singaporensis is a junior heterotypic synonym of
K. variicola and some studies, even with the technique we used, still report the first as a different species (
17). Even more,
K. oxytoca is known to have a similar antimicrobial resistance profile to that of
K. pneumonia.
Surprisingly in this survey the first was even less resistant to the antibiotics usually indicated in the Neonatal Service. Contrastingly,
K. variicola seems to be the most dangerous strain as one of the registered cases showed resistance against 9 antibiotics, and probably more, however, in the moment of the analysis, the equipment ran out of reagents. With the available information the SR ratio reflected the severity of
K. variicola in this exercise of neonatal infections. Our results illustrates the possibility that as
K. variicola was very recently described as a new bacterial species and is very closely related to
K. pneumoniae, it might be the case that some isolates, which were initially classified as
K. pneumoniae, were actually
K. variicola (
18), being the cases of greatest suspicion to those with higher mortality (
19).
Research concerning antibiotic resistance profiles of
Klebsiella isolates are diverse, for example, Vasaikar et al. reported, in South Africa, high antibiotic resistance in decreasing order to penicillins, cephalosporins, folate pathway inhibitors, monobactams, and aminoglycosides. A percentage of low resistance was observed in carbapenems, aminoglycosides (only Amikacin), glycylcyclines (Tigecycline), cephamycins (Cefoxitin), quinolone (Levofloxacin), phosphonic acids (Fosfomycin), antipseudomonal penicillins + β-lactamase inhibitor (pip/tazo), and fluoroquinolones (Ciprofloxacin), which can be considered for treatment of
Klebsiella species (
3). In contrast, in Mexico, the option of quinolones would not be so useful.
Although our sample is low, in a previous work done by Dong et al., (
20), from a sample of 96 cases of neonatal sepsis, 19 were Gram-negative bacteria and only 10 cases were
K. pneumoniae subsp., which exhibited full resistance (100%) to amoxicillin, amoxicillin/clavulanate, cefepime, cefoxitin, ceftazidime, cefotaxime, cefuroxime, and piperacillin, a 70.0% cephalothin resistance rate, and no resistance to amikacin, meropenem, or netilmicin. Resistance to carbapenems with varying prevalence has been reported at sites worldwide (
21). Thus, screening Enterobacteriaceae for ESBL production is essential for better antibiotic selection and preventing its further emergence and spread. In our study, fortunately, there was no case of carbapenemase-producing isolation. However, our findings did not consider other types of Enterobacteriaceae.
Finally, talking about the strain identification techniques, nowadays, PCR diagnosis can confirm the presence or absence of bacterial genomic DNA, giving a diagnosis to the clinician in a few hours (
22). Furthermore, molecular tests based on multiplex real-time quantitative PCR (
23) could be more useful in cases of neonatal sepsis. However, this technique is very expensive for most of the general hospitals and not affordable for the health systems of many low income countries. In the case of Mexico, a medium income country, most of the samples of multidrug resistance are not processed by failures in reagent supply or lack of specialized laboratories in all the Mexican states. This study is limited by its retrospective observational design, and nonsystematic sampling of hospital staff may underestimate the true burden of BSI. Despite the limitations, we have determined through molecular techniques that
Klebsiella species are scarcely known and hardly reported in Latin America.
A future action should be the design of antibiotic-decision flowcharts based on the resistance and clinical parameters as well as studies available in general hospitals. It remains pending the use of new alternatives to treat neonatal infections. For example, our group has explored the use of triazoles obtained by “Via click” against
Candida albicans (
24), however, this type of compounds are far from being clinically approved yet. Another point of view has been the re-evaluation of known antibiotics such as colistin (
25).